DSB: Drug Shortages July 2015
Several drugs continue to be in short supply, posing significant problems for patients. Foremost on this list is leflunomide (Arava) which is backordered for both 10 mg and 20 mg tablets.
Leflunomide Shortage

Several drugs continue to be in short supply, posing significant problems for patients. Foremost on this list is leflunomide (Arava) which is backordered for both 10 mg and 20 mg tablets.
Leflunomide Shortage
Karmacharya and colleages have reviewed 33 cases of rituximab-induced serum sickness. Half of these patients had the classic triad of SS fever, rash, and arthralgia and a self-limiting course. The time to onset after infusion was greater with the first dose of rituximab c
Behcet's disease is difficult to manage, especially if the goal is to avoid corticosteroids.
Defects in protein citrullination and its consequences in patients with RA have been studied widely in the recent decade. It appears that autoantibodies, including those against citrullinated proteins, are of diagnostic and prognostic relevance.
A retrospective review of 1285 US male veterans showed the prevalence of inflammatory eye disease to be 2%. Uveitis was most common (most being anterior uveitis), followed by keratitis, scleritis, episcleritis, and acute ischemic optic neuropathy.
These abstracts and presentations were presented last week on the 12th and 13th of June at the EULAR 2015 annual meeting in Rome.
These abstracts and presentations were presented 12 June at the EULAR 2015 annual meeting.
EULAR 2015 started the afternoon of Wednesday June 10th.
I was recently asked, “what is the best kind of arthritis to have?”
Fibromyalgia is a noninflammatory disorder. However, there are patients with prolonged morning stiffness, subjective joint swelling and many with modest-to-moderate elevations of acute-phase reactants.
Hydroxychloroquine is one of many medications frequently used in rheumatology practice.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.